GlassScriptPhysician profile
Joseph Andre Louis
NPI 1295827798
$1,782.26
in general payments reported to CMS, 2019-2025
15 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.98 · 2020: $184 · 2021: $276 · 2022: $434 · 2023: $245 · 2024: $359 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $475.66 | 2021-2025 | |
| Exact Sciences Corporation | $369.03 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $338.43 | 2020-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $181.63 | 2020-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $94.34 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.75 | 2022-2024 | Jardiance, Tradjenta |
| Pfizer INC. | $45.35 | 2022-2024 | |
| Strongbridge US INC. | $39.56 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $36.27 | 2023-2025 | Farxiga, Airsupra |
| Philips North America LLC | $33.56 | 2019-2024 | (Ck7) Extended Holter |
| Eisai INC. | $25.53 | 2024 | |
| Phadia US INC. | $16.95 | 2019 | |
| Ironwood Pharmaceuticals, INC | $15.74 | 2022 | |
| Allergan, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.